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Pancreatic ductal adenocarcinoma (PDAC) is ranked 
the fourth most common cause of cancer related deaths 
in western countries with a 5-year survival rate of less 
than 8% (1). It is estimated to be even the second most 
common cause by 2030 as there are no successful treatment 
options (2). Due to the lack of early and specific symptoms 
as well as non-invasive biomarkers, the majority of patients 
is diagnosed at an advanced and already metastasized 
disease stage, where palliative treatment remains the only 
option (3). Thus, in order to improve the dismal prognosis 
of PDAC patients, a much better understanding of PDAC 
evolution is urgently needed allowing earlier detection of 
the disease and providing novel therapeutic modalities. 
It is well appreciated that the most common precursor 
lesion of PDAC is the pancreatic intraepithelial neoplasia 
(PanIN) (4). According to the progression model (5,6) and 
supported by genetic studies, PanINs develop from low-
grade to high-grade lesions finally leading to an invasive 
carcinoma. This progression is characterized and driven 
by the acquisition of genetic (and epigenetic) alterations. 
In fact, mutations in the oncogene kras, being one of 
the earliest genetic alterations, are present in 99% of 
even early low-grade PanINs (PanIN1) (5,6). In resected 
PDAC tissues, PanINs are often found in and around the 
tumor mass (7). Genetic analysis revealed that PanINs and 
adjacent carcinoma tissues share many common mutations 
albeit some mutations are apparently acquired not until the 
carcinoma stage (8,9). These data indicate that PDAC may 
origin from neighboring PanINs. However, the biology 
and genetic relationship between PanINs and PDAC and 
thereby PDAC evolution is still poorly understood. 
Murphy et al. showed that pancreatic ductal epithelial 
cells at the PanIN stage already acquire a pronounced 
mutational burden, but still remain non-invasive, indicating 
that a long preneoplastic/premalignant stage precedes the 
onset of an invasive PDAC which requires further genetic 
and chromosomal abberations (8). In contrast, Notta 
et al. provide experimental evidence that some PDACs do 
not progress from PanINs in a linear and slow manner. 
They demonstrated in a certain number of PDACs 
complex rearrangement alterations presumably leading to 
simultaneous rather than sequential acquisition of malignant 
traits including invasive abilities (10). In light of these 
findings, the recently published study by Makohon-Moore 
et al. provides further insights into the understanding of how 
PDACs may evolve from PanINs (11). In their study, the 
authors envisioned three distinct scenarios for the evolution 
of PDAC from PanINs: (I) PanINs and PDAC do not have 
any somatic gene mutations in common and thus develop 
independently from each other; (II) certain mutations 
(passenger as well as driver mutations) are found in both 
PanINs and PDAC, however, PDAC contains additional 
alterations which are not found in PanINs, implying the 
existence of a common ancestral cell of PanINs and PDAC 
but the common ancestral as well as the founding PanIN 
cell yet lack genetic hits which are required to form a 
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malignant PDAC; (III) PanINs and PDAC share all driver 
mutations and some passenger mutations implying that the 
common ancestral cell has acquired all alterations required 
for malignant PDAC including invasive capabilities. 
To distinguish between these three scenarios, whole-
exome sequencing with subsequent phylogenetic analysis 
was performed of laser-capture microdissected PanINs 
and PDAC isolated each from 8 PDAC patients. In each 
of them, PanINs (PanIN2 or PanIN3) were determined 
in an anatomically region distinct from PDAC. Analysis of 
this cohort revealed that in 2 patients PanINs and PDAC 
display a KRASG12D missense mutation but did not share any 
passenger mutations. These findings point towards scenario 
1 that PanIN and PDAC have evolved independently 
and both lesions accidentally acquired the kras mutation 
(considering the high frequency of kras mutations in more 
than 90% of PDAC). In 4 patients, certain driver mutations 
and various passenger mutations identified in the PDAC 
lesions were already found in PanINs of the same pancreas, 
too, but PDAC tissues exhibited additional driver mutations 
and other genetic alterations pointing towards scenario 
2. Finally, analysis of PanINs and PDAC lesions from 2 
patients revealed that PanINs and PDAC share several 
passenger mutations and all driver mutations, supporting 
the view that a single common ancestral cell has already 
acquired invasive abilities leading to its spreading in the 
ductal system, thus pointing towards scenario 3. 
Since PanIN and PDAC lesions were dissected from 
anatomically different sites in the same pancreas, the 
cases pointing towards scenario 2 and 3 support the view 
that single cells—after having acquired distinct genetic 
alterations—are able to disseminate through the ductal 
system to initiate another coevolving neoplasm. Hence, 
PanINs and PDAC lesions in one patient may originate 
from a common ancestral cell involving intraductal 
spreading already at the precursor stage. Certainly, 
further studies on larger patient cohorts are needed to 
further substantiate our understanding according to which 
evolutionary scenario PDAC lesions and spatially divergent 
PanINs develop. In addition to new insights on the tumor 
evolution, these findings also provide further evidence for 
an early dissemination of pancreatic ductal epithelial cells 
already at PanIN stages (12). Studies using cell tracking 
in an endogenous PDAC mouse model system already 
demonstrated that pancreatic ductal epithelial cells in 
PanINs harboring a kras mutation undergo Epithelial-
Mesenchymal-Transition by which they become enabled 
to enter the circulation and seed to the liver. However, 
outgrowth of these early disseminated pancreatic ductal 
epithelial cells to overt metastases requires (genetic/
epigenetic) acquisition of further pro-metastatic traits 
(12-14). Even though it is still not clear whether intraductal 
spreading of pancreatic ductal epithelial cells relies on 
the same mechanisms and invasive traits as systemic 
dissemination, these findings greatly challenge the current 
view that PanINs are regarded as still benign (= non-
invasive) precursor lesions. Accordingly, Notta et al. also 
conclude from their analysis that a single genetic hit 
might provide both invasive and metastatic properties to 
pancreatic ductal epithelial cells additionally implying a 
short latency period between the evolution of an invasive 
clone and its ability to systemically disseminate (10,12). 
Additionally, assuming that acquisition of invasive abilities is 
an early event in PDAC evolution, the question arises what 
might be the potential fitness advantage of this genotypic 
and phenotypic alteration? One explanation might be that 
by early spreading to different sites newly evolved clones 
enhance the probability to encounter environmental 
conditions in which these cells harboring a particular 
genotype are (concomitantly or later) selected, leading 
to clonal expansion and thereby tumor outgrowth. This 
applies to systemic but also intrapancreatic spreading of cell 
clones, because even within one organ microenvironmental 
conditions may vary, e.g., due to the availability of growth 
factors, inflammatory mediators, oxygen or metabolites. 
Accordingly, it could be shown that chronic inflammatory 
microenvironments due to aging reduce the fitness of B 
cell progenitor cells. However, mutations in the oncogene 
NRASV12 or Myc confer a fitness advantage to the cells 
because they become enabled to better cope with aging-
associated functional cellular defects so that these cells 
experience selection by the changed microenvironment (15). 
Hence, further studies are required that unravel which 
genetic and epigenetic alterations provide invasive and 
metastatic abilities (and other phenotypes) already to 
precursor cells. Furthermore, we need to better understand 
whether every PanIN acquires the ability to disseminate 
(intrapancreatically and systemically) or whether non-
invasive and invasive PanINs may exist and, finally, which 
microenvironmental changes are required to select distinct 
geno- and phenotypes in PDAC evolution. Understanding 
the evolutionary aspects of PDAC initiation may then pave 
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